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Background: Blood loss leading to reduced oxygen-carrying capacity is usually
treated with red blood cell transfusions. This study examined the hypothesis that a
hemoglobin-based oxygen-carrying solution can serve as an initial alternative to red
blood cell transfusion.
Methods: In a randomized, double-blind efficacy trial of HBOC-201, a total of 98
patients undergoing cardiac surgery and requiring transfusion were randomly as-
signed to receive either red blood cell units or HBOC-201 (Hemopure; Biopure
Corporation, Cambridge, Mass) for the first three postoperative transfusions. Pa-
tients were monitored before and after transfusion, at discharge, and at 3 to 4 weeks
after the operation for subsequent red blood cell use, hemodynamics, and clinical
laboratory parameters.
Results: The use of HBOC-201 eliminated the need for red blood cell transfusions
in 34% of cases (95% confidence interval 21%-49%). Patients in the HBOC group
received a mean of 1.72 subsequent units of red blood cells; those who received red
blood cells only received a mean of 2.19 subsequent units (P  .05). Hematocrit
values were transiently lower in the HBOC group but were similar in the two groups
at discharge and follow-up. Oxygen extraction was greater in the HBOC group (P
 .05). Mean increases in blood pressure were greater in the HBOC group, but not
significantly so.
Conclusion: HBOC-201 may be an initial alternative to red blood cell transfusions
for patients with moderate anemia after cardiac surgery. In a third of cases,
HBOC-201 eliminated the need for red blood cell transfusion, although substantial
doses were needed to produce this modest degree of blood conservation.
Surgical blood loss and hemodilution associated with cardiac surgerylead to acute postoperative anemia that decreases oxygen-carryingcapacity. Furthermore, many patients enter the operative period withanemia that has been induced iatrogenically by preoperative sampling.These patients and patients requiring urgent cardiac surgery generallydo not have sufficient time or physiologic reserve to donate autolo-
gous blood in advance.1 As a result, allogeneic red blood cell (RBC) transfusion is
needed for at least half of all patients undergoing cardiac surgery.2 It has been
suggested, however, that exposure to allogeneic blood should be minimized to
reduce immunomodulation, incompatibility reactions, and transmission of infectious
agents.3 Hemoglobin-based oxygen-carrying (HBOC) solutions are alternatives to
RBC transfusion that may reduce blood use.
Contemporary HBOC solutions are produced first by purifying hemoglobin
obtained from human or animal blood or by recombinant techniques. Outside the
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RBC, human hemoglobin requires chemical modification by
pyridoxylation to decrease its oxygen affinity. In contrast,
bovine hemoglobin does not require 2,3-diphosphoglycerate
as an allosteric modifier to achieve a physiologic oxygen
half-saturation pressure; instead, the oxygen affinity of bo-
vine hemoglobin is regulated by chloride ion.4 Thus at
physiologic plasma chloride concentration, polymerized bo-
vine hemoglobin has a physiologic oxygen half-saturation
pressure of 35 to 38 mm Hg that, unlike 2,3-diphosphoglyc-
erate–dependent human RBCs, does not diminish with stor-
age.
The purified hemoglobin is then polymerized to decrease
its osmotic pressure and to increase vascular persistence
time. The result is an HBOC solution that can carry and
unload oxygen in the plasma phase. However, clearance
from the circulation and oxidation to methemoglobin, which
occurs in the plasma phase, limit the duration of efficacy,
thus significantly influencing potential clinical applica-
tions.5
HBOC-201 (Hemopure; Biopure Corporation, Cam-
bridge, Mass), is a glutaraldehyde-polymerized bovine he-
moglobin solution. The characteristics of HBOC-201 are
shown in Table 1. This clinical study evaluated the ability of
HBOC-201 to substitute for RBC transfusion in the treat-
ment of moderate anemia resulting from blood loss and
hemodilution after cardiac surgery.
Methods
Study Objectives and Assessments
This was a multicenter (14 sites), randomized, double-blind study
of HBOC-201 administered in the postoperative period, with the
primary objective of evaluating its effect on subsequent allogeneic
blood use. The study design is summarized in Figure 1. Secondary
objectives were to compare hemodynamic, oxygen-transport, and
other physiologic parameters in the treatment groups; to compare
convalescence milestones; and to evaluate safety in patients un-
dergoing cardiac surgery, although interpretation of the safety data
was limited by the sample size.
Clinical parameters (blood pressure, heart rate, and tempera-
ture) were recorded at baseline, on postoperative days (PODs) 1, 2,
3, and 6 (or at discharge, whichever came first), and at follow-up.
Hemoglobin, hematocrit, and clinical chemistry studies were ob-
tained at the same times and at screening. Baseline studies were
performed after the decision to transfuse, just before the first
infusion.
Serial hemodynamic and oxygen-transport data were obtained
before and 30 minutes after the first infusion of the treatment
phase. Arterial and mixed venous blood gas values, heart rate,
systemic and pulmonary arterial pressures, respiratory rate, pulse
oximetry, cardiac output, and pulmonary arterial wedge pressure
were measured. Derived hemodynamic and oxygen-transport vari-
ables were calculated and indexed to body surface area using
standard formulas.
Informed Consent
This study was conducted in compliance with the institutional
review board regulations set forth in the Code of Federal Regula-
tions (21 CFR, Part 56) and the Informed Consent Regulations (21
CFR, Part 50). Each participating institution obtained approval of
the respective institutional review board. Informed consent was
obtained from all patients before surgery.
Study Design
The eligible study population included male and female patients
aged 18 through 80 years in medically stable condition (American
Society of Anesthesiologists class II or III), undergoing elective
cardiac surgery requiring cardiopulmonary bypass and patients
undergoing cardiac surgery who remained hospitalized after diag-
nostic evaluation. Patients who had undergone two or more pre-
vious cardiac surgical operations or who had a complicated surgi-
cal course were excluded. Patients entered the study if they had a
hemoglobin value between 6.5 and 9.0 g/dL or a hematocrit
between 19% and 27% and had transfusion prescribed.
The protocol did not dictate specific transfusion criteria to
participating physicians. A bias caused by differing transfusion
criteria could not be introduced, however, because patients were
not randomly assigned until after the first postoperative transfusion
decision. Moreover, subsequent transfusion decisions were made
under continuing double-blinded protocol. Conventional tech-
niques to avoid allogeneic RBC transfusion (eg, autologous ad-
vance donation, cell salvage, and antifibrinolytic agents) were used
at the physician’s discretion, in accordance with the standard
practice established at each participating medical center; any use
of these modalities was completed before the first transfusion
decision. The rationale for each transfusion decision was recorded.
Eligible patients were randomly assigned at the time of the first
postoperative transfusion decision in the intensive care unit (ICU)
to receive either HBOC-201 or allogeneic RBC transfusion after
completion of surgery through discharge from the ICU; all treat-
ment infusions were administered in the ICU. Patients in each
group received as many as three blinded doses of either HBOC-
TABLE 1. Specifications of HBOC-201 (Hemopure; Biopure
Corporation, Cambridge, Mass)
Characteristic Value
Average molecular weight (kd) 250
Storage requirements Room temperature
(2°C-37°C)
Colloid osmotic pressure (mm Hg) 17
Osmolarity (mOsm/kg) 290-310
Viscosity (cP at 37°C) 1.3
Administration Peripheral or
central vein
pH 7.6-7.9
Physiologic oxygen half-saturation
pressure (mm Hg)
38
Hemoglobin concentration (g/dL,
mean  SD)
13 1
Endotoxin concentration (endotoxin
units/mL)
0.05
Phospholipid concentration (g/mL) 0.1
Cardiopulmonary Support and Physiology Levy et al
36 The Journal of Thoracic and Cardiovascular Surgery ● July 2002
CSP
201 or RBCs within 72 hours after the initial transfusion decision.
The dose of HBOC-201 for the initial transfusion was 60 g in 500
mL; for the two subsequent transfusions (if indicated), the doses
were each 30 g in 250 mL. After 72 hours or three transfusions
(whichever occurred first), all subsequent transfusions in both
treatment groups were unblinded and performed with RBC units.
At no time was any patient’s treatment assignment to be revealed.
All patients who received any treatment infusion to treat post-
operative anemia were included in the primary data analysis. The
proportion of patients in the HBOC group who did not need
allogeneic RBC units was determined, as were the numbers of
RBC units administered in both groups.
Blinding of Infusions
Because RBCs and HBOC-201 are visually distinct, procedures
were established to maintain blinding: bags and tubing were
shielded from view, and results of specific laboratory tests (eg,
plasma hemoglobin and hematocrit) were not made available to
blinded personnel. Unblinded personnel were available at each site
to administer infusions and to ensure patient safety but did not
otherwise make patient care decisions. An external regulatory
consultant (Covance, Princeton, NJ) validated adherence to all
blinding procedures.
Blinded doses of HBOC-201 or allogeneic RBC units were
administered for as many as the first three transfusion decisions in
the ICU within 72 hours after surgery. Transfusions were admin-
istered by means of a dedicated, shielded intravenous line in either
a peripheral or central vein; blinded personnel did not administer
these infusions. For both treatment groups, after the initial three
blinded transfusions all subsequent transfusions were unblinded
and with RBC units.
Patient treatment assignments were not revealed. Investigators
retained the option to administer RBC units unblinded at any time
during the study as needed. In such cases, patients continued in the
study and underwent subsequent evaluations as required by the
protocol.
Statistical Methods
Data are expressed as the mean  SEM or as the median. All
statistical tests were 2-sided. The proportion of patients within the
HBOC group who needed no RBC transfusions was summarized
with a 2-sided 95% confidence interval.
The numbers of RBC units transfused were analyzed with the
nonparametric Kruskal-Wallis test because the data were not nor-
mally distributed (Shapiro-Wilk statistic HBOC group 0.71, P 
.0001; RBC group 0.84, P  .0001). Mortality and adverse event
rates were compared with the Fisher exact test. Changes in hemo-
dynamics and laboratory variables were subjected to Wilcoxon
tests.
Results
Ninety-eight patients were randomly assigned, 48 patients
to the RBC group and 50 to the HBOC group. Among the
14 sites involved in this trial, the number of patients studied
at each site ranged from 2 to 18. The two groups were
comparable for baseline characteristics examined (Table 2).
Forty-four patients in each group had follow-up visits 3 to 4
weeks after surgery; 9 patients who did not have follow-up
visits were interviewed by telephone regarding subsequent
transfusion or significant illness.
Effect of HBOC-201 on Later Allogeneic Transfusion
The indications for each of as many as three clinical trial
infusions are summarized in Table 3. The numbers of sub-
sequent RBC units transfused in the two treatment groups
up to study completion or the time of an intercurrent illness
or complications necessitating RBC transfusion are summa-
rized in Table 4. Seventeen patients in the HBOC group
(34%, 95% confidence interval 21%-49%) did not receive
allogeneic RBC units during the study. In the RBC group,
105 RBC units were subsequently administered to 48 pa-
tients (mean 2.19 units); in the HBOC group, 91 RBC units
Figure 1. Study protocol. Study-related procedures and monitoring, from screening through follow-up, are depicted.
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were subsequently administered to 50 patients (mean 1.72
units). The difference in the number of RBC units trans-
fused as a result of administering HBOC-201 to treat post-
operative anemia represented a mean reduction of 0.47 RBC
unit per patient (Kruskal-Wallis P  .05).
The numbers of patients requiring postoperative clotting
factor replacement are summarized in Table 4. There were
no significant differences between the two study groups.
Hemoglobin and Hematocrit
Hematocrit and total hemoglobin were similar at screening
in the two treatment groups (Figure 2, A and B). Hematocrit
and total hemoglobin concentration decreased (P  .001)
from screening to baseline, when the transfusion decision
was made. Decreases from screening values to baseline
were similar in the two groups (P  .24).
Patients in the HBOC group had significantly decreased
(P .001) hematocrit and total hemoglobin levels on PODs
1, 2, and 3 relative to the RBC group. By POD 6, these
variables were equivalent for the two groups.
At baseline, mean plasma hemoglobin levels were low
and similar in the two groups (RBC group 0.01 g/dL vs
HBOC group 0.03 g/dL). For the HBOC group, mean
plasma hemoglobin levels were increased relative to base-
line on POD 1 (1.54  0.10 g/dL), POD 2 (0.86  0.08
g/dL), and POD 3 (0.45  0.07 g/dL) but had decreased
TABLE 2. Demographic and baseline characteristics of patients in the RBC and HBOC-201 treatment groups
Characteristic RBC group HBOC-201 group P value
Age (y, mean  SE) 67.0 1.3 65.7 1.5 .51
Sex (% male) 60 64 .72
Body surface area (m2, mean  SE) 1.90 0.03 1.91 0.04 .93
Oxygen-transport parameters
Hemoglobin (g/dL, mean  SE) 7.87 0.13 8.07 0.13 .28
Hematocrit (%, mean  SE) 23.1 0.4 23.9 0.5 .17
Smoking history (% current) 25 30 .39
Surgery (No.)
Coronary artery bypass grafting 33 35 .82
Valve 7 8
Combined coronary artery bypass grafting and valve 8 7
Cardiopulmonary bypass time (h, mean  SE) 1.98 0.12 1.97 0.11 .999
Coronary artery bypass grafting anastomoses (No., mean  SE) 3.5 0.8 3.3 1.0 .88
Patients receiving intraoperative allogeneic RBC transfusion (No.) 15 (31%) 16 (32%) .999
TABLE 3. Indications for clinical trial infusions
Infusion
Primary reason for
administration
RBC group
(n  48)
HBOC group
(n  50)
1 Total hemoglobin 34 (74%) 43 (86%)
Hematocrit 20 (42%) 21 (42%)
Blood pressure/heart rate 7 (15%) 10 (22%)
Blood loss replacement 0 1 (2%)
Other 7 (11%) 14 (28%)
2 No. receiving second infusion 31 34
Total hemoglobin 22 (82%) 29 (94%)
Hematocrit 0 0
Blood pressure or heart rate 9 (33%) 0
Blood loss replacement 0 2 (7%)
Other 8 (30%) 12 (39%)
3 No. receiving third infusion 12 21
Total hemoglobin 12 (100%) 20 (95%)
Hematocrit 0 0
Blood pressure/heart rate 0 0
Blood loss replacement 0 1 (5%)
Other 0 4 (19%)
Note that some patients had more than one indication for infusion.
TABLE 4. Patients receiving specified number of RBC units
and patients receiving specified number of allogeneic clot-
ting factor replacement units
RBC
(n  48)
HBOC
(n  50) P value
RBC units transfused
0 0 (0%) 17 (34%)
1 15 (31%) 8 (16%)
2 20 (42%) 11 (22%)
3 10 (21%) 6 (12%)
4 0 (0%) 4 (8%)
5 0 (0%) 3 (6%)
6 1 (2%) 0 (0%)
7 2 (4%) 1 (2%)
Units per patient
(mean  SE)
2.19 0.20 1.72 0.26*
Patients receiving allogeneic
clotting factor replacement
units (No.)
Fresh frozen plasma 7 2 .192
Platelets 5 7 NS
Cryoprecipitate 1 1 NS
NS, Not significant.
* P  .05 by Kruskal-Wallis test.
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toward baseline values by POD 6 (0.01  0.01 g/dL). For
the RBC group, mean plasma hemoglobin never exceeded
0.02 g/dL. At discharge and follow up, however, these
parameters were similar in the two treatment groups.
For the 17 patients in the HBOC group who did not
receive any RBC transfusions, the mean total hemoglobin
concentration increased significantly from baseline (8.02 
0.18 g/dL) to POD 6 (9.35  0.22 g/dL, P  .0003). For
these 17 patients, the mean plasma hemoglobin value on
POD 6 was 0.04  0.01 g/dL.
Methemoglobin levels (as a percentage of total hemo-
globin) were available for some study patients on PODs 1
and 2. In the RBC group, baseline (n  28) was 0.95% 
0.09%, day 1 (n 16) was 0.69% 0.08%, and day 2 (n
7) was 0.44%  0.12%. In the HBOC group, baseline (n 
28) was 0.92% 0.09%, day 1 (n 12) was 3.58 0.55%
(P  .001 vs RBC group), and day 2 (n  8) was 4.56 
0.25% (P  .001 vs RBC group).
Hemodynamic and Oxygen-Transport Parameters
Table 5 summarizes changes in hemodynamic and oxygen-
transport variables from baseline to after the initial infusion.
There was a small but statistically significantly greater
decrease in mean cardiac index for the HBOC group; the
range of changes in cardiac index overlapped among pa-
tients in the two treatment groups.
The increases in systemic and pulmonary arterial pres-
sures were greater for the HBOC group. Pulse oximetry–
derived oxygen saturation was decreased in the HBOC
group, consistent with the rightward shifted oxyhemoglobin
dissociation curve of HBOC-201.6
There were no statistically significant differences be-
tween the two groups with respect to changes in heart rate,
pulmonary arterial wedge pressure, oxygen delivery index,
oxygen consumption index, or arterial PO2.
Clinical Variables
Maximum changes from baseline from first transfusion to
discharge were assessed for temperature, systolic and dia-
stolic blood pressures, mean arterial pressure, and heart rate
(Table 6). There were no statistically significant differences
in these variables between groups.
For the two treatment groups, maximum change from
baseline from first treatment to discharge were compared for
creatinine, lipase, aspartate aminotransferase, and alanine
aminotransferase. The maximum increase in aspartate ami-
notransferase activity (IU/L) was greater in the HBOC
group (RBC median 6, interquartile range 5 to 32 vs
HBOC median 22, interquartile range 15-83, P  .033).
Maximum increases in alanine aminotransferase activity
(IU/L) (RBC median 6, interquartile range 1-13 vs HBOC
median 20, interquartile range 6-47), creatinine (mmol/L)
(RBC median 18, interquartile range 9-35 vs HBOC median
18, interquartile range 0-35), and lipase activity (IU/L)
(RBC median 137, interquartile range 26-235 vs HBOC
median 141, interquartile range 60-400) were similar for the
two groups. No associated clinical hepatic, pancreatic, or
renal abnormalities were apparent.
The two groups had similar hospital stays (P  .29;
Figure 3) and ICU stays (P  .16).
Safety
One patient in the HBOC group died of aspiration pneumo-
nia on POD 3; there were no deaths in the RBC group.
Complications were reported for 16 patients: renal failure
occurred in 1 patient in each treatment group, infections
occurred in 3 patients in each treatment group, and arrhyth-
mias occurred in 3 patients in the HBOC group and 5
patients in the RBC group.
Because of laboratory interference, bilirubin levels could
not be determined during times when HBOC-201 was ad-
ministered. However, jaundice occurred in 14 patients in the
Figure 2. Serial hematocrit (A) and hemoglobin (B) measurements
for patients in HBOC and RBC groups.
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HBOC group, but no patients in the RBC group. The oc-
currence of jaundice was not related to the number of units
of HBOC-201 infused, and all cases of jaundice had re-
solved by the time of hospital discharge.
Discussion
This study was designed to evaluate the blood-conserving
potential of a hemoglobin-based oxygen carrier, HBOC-
201, when administered to patients immediately after car-
diac surgery. Administration of HBOC-201 at the doses
used in this study eliminated the need for postoperative
RBC transfusions in 34% of cases. The 17 patients in the
HBOC group who did not receive any RBC units had
restoration of hematocrit at hospital discharge and required
no additional RBC transfusions after discharge. Jaundice
and elevated aspartate aminotransferase and alanine amino-
transferase activities were observed in the HBOC group.
The two treatment groups were similar in convalescence
milestones and hospital stay.
The decision to transfuse a patient undergoing cardiac
surgery takes into account multiple factors, including he-
moglobin level, hemodynamics, and comorbid conditions
(eg, age, cardiac reserve, lung disease), consistent with the
conclusions of a National Institutes of Health Consensus
Panel that no single measure can replace good clinical
judgment as the basis for decision making regarding peri-
operative transfusion.7 Given this prevailing clinical prac-
tice, investigators in this study were allowed to transfuse
according to their usual clinical judgment for this patient
population. Investigator bias was minimized by adherence
to a blinding protocol, although potentially revealing prop-
erties of HBOC-201 (eg, half-life, appearance of jaundice)
may have limited the effectiveness of this blinding protocol.
This study suggests that HBOC-201 maintained oxygen
transport. Oxygen content calculations showed that HBOC-
201 was similar to RBCs. Oxygen extraction was increased
slightly in the HBOC group, associated with a decrement in
cardiac index. Importantly, clinical objectives were
achieved with lower mean hematocrit and total hemoglobin
TABLE 5. Changes in hemodynamic and oxygen-transport parameters
RBC group HBOC group P value
Cardiac index (L/[min  m2]) .02
Baseline 2.92 0.10 3.03 0.10
Change from baseline to after initial infusion 0.05 0.06 0.27 0.09
Mean arterial pressure (mm Hg) .01
Baseline 73.2 1.5 77.5 1.6
Change from baseline to after initial infusion 5.6 2.0 12.4 1.9
Mean pulmonary arterial pressure .004
Baseline 21.9 1.0 23.9 1.7
Change from baseline to after initial infusion 1.2 0.6 4.2 0.9
Pulse oximetry-derived arterial oxygen saturation (%) .01
Baseline 98.4 0.3 98.4 0.3
Change from baseline to after initial infusion 0.4 0.4 1.9 0.6
Arterial oxygen content (mL/dL) .03
Baseline 10.7 0.2 11.1 0.2
Change from baseline to after initial infusion 1.9 0.2 1.1 0.2
Oxygen extraction (%) .05
Baseline 37 2 34 2
Change from baseline to after initial infusion 2 1 2 2
Heart rate (beats/min) NS
Baseline 94.3 2.0 93.4 2.4
Change from baseline to after initial infusion 2.2 1.0 2.3 1.5
Pulmonary artery wedge pressure (mm Hg) NS
Baseline 11.9 1.0 12.4 0.9
Change from baseline to after initial infusion 1.5 0.7 1.5 0.8
Oxygen delivery index (mL oxygen/[min  m2]) .143
Baseline 32.3 1.6 34.1 1.5
Change from baseline to after initial infusion 3.3 0.9 0.5 1.6
Oxygen consumption index (mL oxygen/[min  m2]) NS
Baseline 11.7 0.5 12.1 1.1
Change from baseline to after initial infusion 0.7 0.6 0.1 0.9
Arterial Po2 (mm Hg) NS
Baseline 156 12 153 10
Change from baseline to after initial infusion 2.5 11.0 2.2 8.9
All data are mean  SE. NS, Not significant.
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levels. The oxygen-transport properties of HBOC-201 were
established in an early experimental study in which animals
underwent near-total blood exchange (average hematocrit
2.4%) with either crystalloid solution or HBOC-201.8 No
control animals survived in that study, whereas HBOC-201
was shown to meet oxygen-transport requirements and pro-
duce long-term survival.
In this study cardiac index was lower in the HBOC
group, although the difference in oxygen delivery index was
not significant. In animals with severe hemodilution and
tissue hypoxia, HBOC-201 produced increases in oxygen
extraction, decreases in cardiac output, and increased tissue
oxygenation.9 Decreased cardiac output was also reported in
a study of humans with hemodilution who were given small
doses of HBOC-201.10 The mechanism of this decrease in
cardiac index is not known but may have been related to
blood pressure increases.
Patients may have low systemic vascular resistance after
cardiac surgery, necessitating the use of -agonists. This
can result from sedation, preoperative use of vasodilators or
antihypertensive drugs, or postoperative anemia, which de-
creases blood viscosity. Thus increases in systemic blood
pressure produced by HBOCs may have an advantage in
this clinical setting, although extreme blood pressure in-
creases are potentially detrimental. As noted in Table 3,
when second or third infusions were needed in the HBOC
group, they were not indicated because of hemodynamic
considerations, consistent with this observed physiologic
effect.
In clinical11 and experimental12 studies of HBOCs in the
treatment of severe hemorrhagic shock, increased mortality
was suggested, particularly when HBOC preparations were
used that increased systemic vascular resistance. Increased
blood pressure may result from local vascular nitric oxide
binding or from release of endothelin 1.13,14
The findings of this trial illustrate an important efficacy
limitation of this class of materials. HBOC-201 has a short
plasma half-life of approximately 24 hours. Furthermore,
HBOCs can oxidize to methemoglobin in the plasma phase,
thus further limiting efficacy.5 In this trial, methemoglobin
levels were available for some patients. For HBOC-201
recipients, approximately 15% of circulating HBOC was in
the form of methemoglobin on POD 1; by POD 2, this
increased to approximately 40%. As a result, use of as much
as 120 g HBOC hemoglobin (roughly equivalent to 2 units
of allogeneic RBCs) resulted in a modest degree of alloge-
neic blood conservation (approximately half a unit). Clini-
cal applications must take these efficacy issues into consid-
eration.
The restoration of hematocrit in HBOC-201 recipients
suggests that its short half-life of efficacy is offset by other
effects on the endogenous RBC mass. In a recently pub-
lished clinical trial, a human-derived HBOC preparation
with a very short half-life was also able to produce a small
but significant effect on blood use in patients undergoing
cardiac surgery.15 Patients in our HBOC group had a de-
creased mean hematocrit during the early PODs, but mean
hematocrit was similar in the two groups by POD 6. The
mean total hemoglobin concentration for the 17 patients in
the HBOC group who did not require allogeneic RBC
transfusions increased from 8.0 g/dL at baseline to 9.4 g/dL
at POD 6, when plasma hemoglobin had decreased to neg-
ligible levels. In the RBC group, the increase in hematocrit
resulted from RBC transfusions; in the HBOC-201 group,
however, the increase may have been due to an effect of
TABLE 6. Maximum changes in vital signs from baseline to hospital discharge
RBC group HBOC group P value
Temperature (°C) NS
Baseline (mean  SE) 36.9 0.2 37.1 0.1
Change from baseline to after initial infusion (mean SE) 0.8 0.1 0.8 0.1
Systolic blood pressure (mm Hg) .081
Baseline (mean  SE) 111.0 2.4 118.0 2.4
Change from baseline to after initial infusion (mean SE) 29.7 2.8 36.7 2.7
Range 10 to 70 4 to 89
Diastolic blood pressure (mm Hg) NS
Baseline (mean  SE) 56.1 1.2 59.4 1.5
Change from baseline to after initial infusion (mean  SE) 20.2 1.7 21.1 1.3
Range 12 to 46 0 to 41
Mean arterial pressure (mm Hg) NS
Baseline (mean  SE) 74.4 1.4 78.9 1.5
Change from baseline to after initial infusion (mean  SE) 21.6 1.9 23.9 1.5
Range 10 to 52 4 to 48
Heart rate (beats/min) NS
Baseline (mean  SE) 94.3 2.0 93.4 2.4
Change from baseline to after initial infusion (mean  SE) 12.7 2.7 10.5 2.1
NS, Not significant.
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HBOC-201 on RBC production. In a previous study,
HBOC-201 increased serum iron, ferritin, and erythropoie-
tin levels.16
Toxic reactions associated with early HBOCs included
renal dysfunction, severe hypertension, and pancreatitis.17,18
In the this trial, 1 patient in each group had clinically
significant renal dysfunction. There was no difference in
maximum blood pressure between groups, and no cases of
clinical pancreatitis were observed. This study was not
powered to find differences in morbidity or mortality, so no
definite conclusions can be drawn about the risks associated
with HBOC-201 relative to blood.
In summary, HBOC solution treatment of moderate post-
operative anemia allowed avoidance of RBC transfusion in
approximately a third of uncomplicated cases of cardiac
surgery, conserving blood. In addition, patients in the
HBOC group had recovery of sufficient hematocrit by dis-
charge, possibly attributable to increased RBC production
(hematinic effect). Limitations of efficacy included proto-
col-defined dose and treatment time, short half-life of effi-
cacy relative to RBC transfusion, and HBOC oxidation to
methemoglobin, all of which resulted in the need to use
large amounts of HBOC hemoglobin to achieve even a
modest degree of RBC conservation. Elimination of RBC
transfusion in most cases may require even larger doses or
HBOC solutions with a longer effective half-life. If the
treatment of moderate surgical anemia observed in this
study can be extrapolated to broader clinical applications,
HBOCs may address an important medical need. Specifi-
cally, HBOCs may be appropriate when a need to transfuse
RBCs is seen but avoidance of transfusion is desired or
compatible RBCs are not available.
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Figure 3. Proportions of patients remaining hospitalized in terms
of days after cardiac surgery for HBOC and RBC groups. Hospital
stays were similar (P  .29).
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